| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 159.88 | 43.3% |
| Total Income | 159.88 | 43.3% |
| Expenditure | 949.35 | 648.9% |
| PBT | -789.68 | 5685.2% |
| Net Profit | -790.16 | 5282.6% |
| OPM | — | |
| NPM | — | |
| EPS | -13.43 | 4376.7% |
Mirum Pharmaceuticals Reports Q1 2026 Net Product Sales of $159.9 Million
07 May 2026 · 7 May, 1:40 am
Summary
Mirum Pharmaceuticals reported Q1 2026 financial results, with net product sales of $159.9 million. LIVMARLI® sales grew by 55% compared to Q1 2025, reaching $113.8 million, while Bile Acid Medicines sales increased by 20% to $46.1 million. The company raised its full-year revenue guidance to $660 to $680 million. Mirum also in-licensed zilurgisertib for FOP, which has been granted FDA Priority Review.
Key Highlights
- 1
Mirum Pharmaceuticals reported Q1 2026 net product sales of $159.9 million.
- 2
The company increased its 2026 net product sales guidance to $660 to $680 million.
- 3
LIVMARLI® net product sales were $113.8 million in Q1 2026, representing 55% growth over Q1 2025.
- 4
Bile Acid Medicines net product sales were $46.1 million in Q1 2026, a 20% increase compared to Q1 2025.
- 5
The volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC) met its primary endpoint.
- 6
The brelovitug Phase 2b portion of the AZURE-1 study in chronic hepatitis delta virus (HDV) met its primary endpoint.
- 7
Mirum in-licensed exclusive worldwide rights to zilurgisertib (ALK2 inhibitor) for FOP, with the FDA granting Priority Review and setting a PDUFA date of September 26, 2026.
Management Comments
Chris Peetz
2026 is off to an excellent start, driven by strong commercial momentum, the recent VISTAS and AZURE-1 topline results, disciplined clinical execution, and continued expansion of our pipeline. We also announced today the in-license of zilurgisertib, a once-daily oral ALK2 inhibitor for fibrodysplasia ossificans progressiva from Incyte. Zilurgisertib has completed a pivotal study for FOP and its NDA has been accepted, creating the potential for an additional product launch for our rare genetic disease team later this year. We’re grateful to Incyte for all the work they have conducted on this program and look forward to potentially bringing another high impact medicine to patients.
Informational and educational content only. Not investment advice.